A study on the efficacy of DS-2325a for patients with Netherton Syndrome was terminated based on a business decision by the sponsor.
1 Discontinued Research Program
All entries for: Daiichi Sankyo
January 20, 2025
Daiichi Sankyo
Discontinued Research
Basking Ridge, NJ
10,001-50,000 employees
Disease Area: Rare Diseases
Drug Type: Biologic
